Volume 10, Issue 3 pp. 215-220

ORIGINAL ARTICLE

Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study

Sheng-Mou HSIAO,

Sheng-Mou HSIAO

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei, Taiwan

Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan, Taiwan

Search for more papers by this author

Ting-Chen CHANG,

Ting-Chen CHANG

Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Chi-Hau CHEN,

Chi-Hau CHEN

Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Wen-Yih WU,

Wen-Yih WU

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei, Taiwan

Search for more papers by this author

Ho-Hsiung LIN,

Corresponding Author

Ho-Hsiung LIN

[email protected]

Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

Correspondence: Professor Ho-Hsiung Lin, MD, PhD, Department of Obstetrics and Gynecology, National Taiwan University Hospital, No. 8, Chung-Shan South Road, Taipei 100, Taiwan. Tel: +886223123456 ext 71557; Fax: +886223114965. Email: [email protected]Search for more papers by this author

Sheng-Mou HSIAO,

Sheng-Mou HSIAO

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei, Taiwan

Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan, Taiwan

Search for more papers by this author

Ting-Chen CHANG,

Ting-Chen CHANG

Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Chi-Hau CHEN,

Chi-Hau CHEN

Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Wen-Yih WU,

Wen-Yih WU

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei, Taiwan

Search for more papers by this author

Ho-Hsiung LIN,

Corresponding Author

Ho-Hsiung LIN

[email protected]

Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

First published: 23 April 2017

https://doi.org/10.1111/luts.12167

Citations: 8

The work was carried out at the Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.

Share a link

Email
Wechat
Bluesky

Abstract

Objectives

The impact of mirabegron on clinical outcome and urodynamic parameters may be important for clinical practice. Thus, the aim of this study was to compare the clinical outcomes and urodynamic effects of mirabegron (Betmiga 50 mg) versus tolterodine (Detrusitol ER 4 mg) treatment for women with overactive bladder syndrome (OAB).

Methods

Women with OAB were randomized to receive 12 weeks of mirabegron 50 mg, tolterodine extended-release 4 mg or placebo treatment. The clinical outcomes and urodynamic effects were compared between the subgroups.

Results

Thirty-three women completed 12 weeks of mirabegron (n = 12), tolterodine (n = 12) or placebo (n = 9) treatment. A significant increase in the volumes at strong desire to void and a decrease in the daytime frequency episodes were identified in the mirabegron and tolterodine groups (all P < 0.05). Nonetheless, a decrease in the total voided volume was identified following mirabegron treatment but not tolterodine (P = 0.02).

Conclusions

Mirabegron and tolterodine exhibit similar changes in the urodynamics and bladder diary parameters. However, mirabegron may decrease the total voided volume. These findings may serve as an initial guide or assist in consultations regarding the treatment of OAB patients with mirabegron.

References

1Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987–1006.
10.1111/j.1464-410X.2007.07205.x
CAS PubMed Web of Science® Google Scholar
2Hsiao SM, Liao SC, Chen CH, Chang TC, Lin HH. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects. Maturitas 2014; 79: 428–34.
10.1016/j.maturitas.2014.08.009
PubMed Web of Science® Google Scholar
3Hsiao SM, Su TC, Chen CH, Chang TC, Lin HH. Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects. Maturitas 2014; 79: 65–9.
10.1016/j.maturitas.2014.06.001
CAS PubMed Web of Science® Google Scholar
4Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 2011; 37: 1084–91.
10.1111/j.1447-0756.2010.01493.x
CAS PubMed Web of Science® Google Scholar
5Kuo HC, Lee KS, Na Y et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn 2015; 34: 685–92.
10.1002/nau.22645
CAS PubMed Web of Science® Google Scholar
6Yamaguchi O. β3-adrenoceptors in human detrusor muscle. Urology 2002; 59: 25–9.
10.1016/S0090-4295(01)01635-1
PubMed Web of Science® Google Scholar
7Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R. Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodyn 2003; 22: 338–42.
10.1002/nau.10130
CAS PubMed Web of Science® Google Scholar
8Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn 2010; 29: 771–6.
10.1002/nau.20826
CAS PubMed Web of Science® Google Scholar
9Takasu T, Ukai M, Sato S et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2- hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007; 321: 642–7.
10.1124/jpet.106.115840
CAS PubMed Web of Science® Google Scholar
10Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543–62.
10.1016/j.eururo.2008.06.047
CAS PubMed Web of Science® Google Scholar
11Nitti VW, Khullar V, van Kerrebroeck P et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013; 67: 619–32.
10.1111/ijcp.12194
CAS PubMed Web of Science® Google Scholar
12Yamaguchi O, Marui E, Kakizaki H et al. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int 2014; 113: 951–60.
10.1111/bju.12649
CAS PubMed Web of Science® Google Scholar
13Chapple CR, Kaplan SA, Mitcheson D et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296–305.
10.1016/j.eururo.2012.10.048
CAS PubMed Web of Science® Google Scholar
14Nitti V, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013; 189: 1388–95.
10.1016/j.juro.2012.10.017
CAS PubMed Web of Science® Google Scholar
15Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013; 63: 283–95.
10.1016/j.eururo.2012.10.016
CAS PubMed Web of Science® Google Scholar
16Herschorn S, Barkin J, Castro-Diaz D et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013; 82: 313–20.
10.1016/j.urology.2013.02.077
PubMed Web of Science® Google Scholar
17Wagg A, Cardozo L, Nitti VW et al. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing 2014; 43: 666–75.
10.1093/ageing/afu017
PubMed Web of Science® Google Scholar
18Hsiao SM, Hsiao CF, Chen CH, Chang TC, Wu WY, Lin HH. Evaluation of bladder diary parameters based on correlation with the volume at strong desire to void in filling cystometry. PLoS One 2013; 8: e69946.
10.1371/journal.pone.0069946
CAS PubMed Web of Science® Google Scholar
19Hsiao SM, Chang TC, Chen CH, Wu WY, Lin HH. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder. Menopause 2017; 24: 100–4.
10.1097/GME.0000000000000730
PubMed Web of Science® Google Scholar
20Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37–49.
10.1016/S0090-4295(02)02243-4
PubMed Web of Science® Google Scholar
21Nixon A, Colman S, Sabounjian L et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005; 174: 604–7.
10.1097/01.ju.0000165461.38088.7b
PubMed Web of Science® Google Scholar
22Homma Y, Yoshida M, Seki N et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology 2006; 68: 318–23.
10.1016/j.urology.2006.02.042
CAS PubMed Web of Science® Google Scholar
23Sand PK. The evaluation of the incontinence female. Curr Probl Obstet Gynecol Fertil 1992; 115: 107–51.
Google Scholar
24Wu WY, Sheu BC, Lin HH. Twenty-minute pad test: comparison of infusion of 250ml of water with strong-desire amount in the bladder in women with stress urinary incontinence. Eur J Obstet Gynecol Reprod Biol 2008; 136: 121–5.
10.1016/j.ejogrb.2007.02.030
PubMed Web of Science® Google Scholar
25Schäfer W, Abrams P, Liao L et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002; 21: 261–74.
10.1002/nau.10066
CAS PubMed Web of Science® Google Scholar
26Maman K, Aballea S, Nazir J et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014; 65: 755–65.
10.1016/j.eururo.2013.11.010
CAS PubMed Web of Science® Google Scholar
27Matsukawa Y, Takai S, Funahashi Y, Yamamoto T, Gotoh M. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology 2015; 85: 786–90.
10.1016/j.urology.2015.01.002
PubMed Web of Science® Google Scholar
28Kamei J, Furuta A, Akiyama Y et al. Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder. Int J Urol 2015; 22: 956–61.
10.1111/iju.12867
CAS PubMed Web of Science® Google Scholar
29Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 2016; 54: 78–82.
10.1038/sc.2015.195
CAS PubMed Web of Science® Google Scholar
30Holmer SR, Hengstenberg C, Mayer B et al. Marked suppression of renin levels by beta-receptor blocker in patients treated with standard heart failure therapy: a potential mechanism of benefit from beta-blockade. J Intern Med 2001; 249: 167–72.
10.1046/j.1365-2796.2001.00786.x
CAS PubMed Web of Science® Google Scholar
31Schroten NF, Gaillard CA, van Veldhuisen DJ, Szymanski MK, Hillege HL, de Boer RA. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev 2012; 17: 191–201.
10.1007/s10741-011-9262-2
CAS PubMed Web of Science® Google Scholar
32Aldehni F, Tang T, Madsen K et al. Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6. Hypertension 2011; 57: 460–8.
10.1161/HYPERTENSIONAHA.110.167130
CAS PubMed Web of Science® Google Scholar
33Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 119 (7 Suppl 1): S47–53.
10.1016/j.amjmed.2006.05.007
CAS PubMed Web of Science® Google Scholar
34Feingold KR, Gavin LA, Schambelan M, Schriock E, Sebastian A, Stern JL. Endocrine disease. In: TE Andreoli, JC Bennett, CCJ Carpenter, F Plum, LH Smith, eds. Cecil Essential of Medicine, 3rd edn. Philadelphia, PA: W.B. Saunders, 1993; 481–92.
Google Scholar
35Wu WY, Hsiao SM, Chang TC, Lin HH. Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction. J Obstet Gynaecol Res 2011; 37: 436–41.
10.1111/j.1447-0756.2010.01370.x
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume10, Issue3

September 2018

Pages 215-220

Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study

Abstract

Objectives

Methods

Results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study

Abstract

Objectives

Methods

Results

Conclusions

References

Citing Literature

References

Related

Information